Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

Presentation TCT Abstracts Posters 2018

Incidence of Clopidogrel Resistance Among South Indian Population Undergoing PCI-A Single Centre Genomic Study of CYP2C19 Polymorphism

Presenter: R. Anantharaman

September 25, 2018

Presentation TCT Abstracts Posters 2018

IMPACT: Improving coronary graft Patency with postoperative Aspirin and Clopidogrel versus Aspirin and Ticagrelor

Presenter: Gerard Devlin

September 25, 2018

Presentation TCT Abstracts Posters 2018

Outcomes of Preoperative Bridging with Intravenous Antiplatelet Therapy in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention

Presenter: Bassel Bou Dargham

September 25, 2018

Presentation TCT Abstracts Posters 2018

Heparin surfaces: Impact of immobilization chemistry for blood contact performance

Presenter: Jennie Forsberg

September 25, 2018

Presentation TCT 2014

When Should Aspirin Be Dropped From Triple Therapy? Musings on Woest and Beyond

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Harvey D. White

September 15, 2014

Presentation TCT 2014

Integrating a WOEST Aspirin Deletion Strategy Into Clinical Practice: When Is it Appropriate?

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Freek W.A. Verheugt

September 14, 2014

Presentation TCT 2014

Featured Lecture: Aspirin, the Most Understood and Misunderstood Antiplatelet Agent

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Anthony A. Bavry

September 14, 2014

Presentation TCT 2014

Aspirin and ADP Antagonists Before and After Coronary Stent Implantation

Presenter: Paul A. Gurbel, Dmitriy N. Feldman

September 14, 2014

Presentation TCT 2013

Aspirin and ADP Antagonists Pre- and Post-coronary Stent Implantation

Presenter: Dmitriy Feldman

October 28, 2013

Presentation TCTAP 2013

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Presenter: Matthew J. Price

April 24, 2013

Presentation TCTAP 2013

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

Presenter: Adnan Kastrati

April 24, 2013

Presentation TCTAP 2012

Evidence-Based Pharmacotherapy Recommendations for PCI, NSTEMI, and STEMI:

Presenter: Gregg W. Stone

April 26, 2012

Advertisement

Incidence of Clopidogrel Resistance Among South Indian Population Undergoing PCI-A Single Centre Genomic Study of CYP2C19 Polymorphism

IMPACT: Improving coronary graft Patency with postoperative Aspirin and Clopidogrel versus Aspirin and Ticagrelor

Outcomes of Preoperative Bridging with Intravenous Antiplatelet Therapy in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention

Heparin surfaces: Impact of immobilization chemistry for blood contact performance

When Should Aspirin Be Dropped From Triple Therapy? Musings on Woest and Beyond

Integrating a WOEST Aspirin Deletion Strategy Into Clinical Practice: When Is it Appropriate?

Featured Lecture: Aspirin, the Most Understood and Misunderstood Antiplatelet Agent

Aspirin and ADP Antagonists Before and After Coronary Stent Implantation

Aspirin and ADP Antagonists Pre- and Post-coronary Stent Implantation

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Counterpoint: The Incremental Benefit Is Small and the Cost-Disadvantages of New DAPT Approaches Are Prohibitive

Evidence-Based Pharmacotherapy Recommendations for PCI, NSTEMI, and STEMI:

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content